The estimated Net Worth of Daniel Abdun Nabi is at least $14 Milione dollars as of 1 June 2024. Mr. Nabi owns over 88 units of Regenxbio Inc stock worth over $3,521 and over the last 18 years he sold RGNX stock worth over $13,710,718. In addition, he makes $318,316 as Independent Director at Regenxbio Inc.
Sign up
Mr. Nabi RGNX stock SEC Form 4 insiders trading
Daniel has made over 30 trades of the Regenxbio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 88 units of RGNX stock worth $1,118 on 1 June 2024.
The largest trade he's ever made was selling 178,515 units of Regenxbio Inc stock on 31 May 2011 worth over $4,387,899. On average, Daniel trades about 7,270 units every 54 days since 2006. As of 1 June 2024 he still owns at least 277 units of Regenxbio Inc stock.
You can see the complete history of Mr. Nabi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Abdun-Nabi biography
Daniel J. Abdun-Nabi J.D. serves as Independent Director of the Company. He has been a Director since August 2016. Mr. Abdun-Nabi served as the Chief Executive Officer of Emergent BioSolutions Inc. (“Emergent”), a publicly held biopharmaceutical company, from March 2018 until his retirement in March 2019, as the President and Chief Executive Officer of Emergent from April 2012 to March 2018 and as the President and Chief Operating Officer of Emergent from May 2007 to March 2012, and he held various other senior management positions at Emergent beginning in 2004. Mr. Abdun-Nabi previously served as General Counsel for IGEN International, Inc. (“IGEN”), a biotechnology company, and its successor BioVeris Corporation, from September 1999 to May 2004. Prior to joining IGEN, Mr. Abdun-Nabi served as Senior Vice President, Legal Affairs, General Counsel and Secretary of North American Vaccine, Inc., a vaccine developer and manufacturer. Mr. Abdun-Nabi has served as a director at Aptevo Therapeutics Inc., a publicly held biotechnology company, since August 2016. He served as a director at Emergent from May 2009 to March 2019. Mr. Abdun-Nabi received an LL.M. in Taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. from the University of Massachusetts, Amherst. Mr. Abdun-Nabi’s qualifications to continue to serve as a member of the Board include his extensive experience in senior management positions at publicly held biopharmaceutical companies, his current and prior service on the boards of such companies and his demonstrated business judgment.
What is the salary of Daniel Nabi?
As the Independent Director of Regenxbio Inc, the total compensation of Daniel Nabi at Regenxbio Inc is $318,316. There are 14 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
How old is Daniel Nabi?
Daniel Nabi is 65, he's been the Independent Director of Regenxbio Inc since 2016. There are 5 older and 14 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
What's Daniel Nabi's mailing address?
Daniel's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Insiders trading at Regenxbio Inc
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas e Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
What does Regenxbio Inc do?
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
What does Regenxbio Inc's logo look like?
Complete history of Mr. Nabi stock trades at Aptevo Therapeutics Inc, Regenxbio Inc e Emergent Biosolutions Inc
Regenxbio Inc executives and stock owners
Regenxbio Inc executives and other stock owners filed with the SEC include:
-
Kenneth Mills,
President, Chief Executive Officer, Executive Director -
Steve Pakola,
Senior Vice President, Chief Medical Officer -
Vittal Vasista,
Chief Financial Officer, Senior Vice President -
Olivier Danos,
Senior Vice President, Chief Scientific Officer -
Curran Simpson,
Senior Vice President - Product Development, Chief Technology Officer -
Kenneth T. Mills,
Pres, CEO & Director -
Vittal K. Vasista,
Chief Financial Officer -
Dr. Olivier Danos Ph.D.,
Chief Scientific Officer -
Curran M. Simpson M.S.,
Chief Operations & Technology Officer -
Patrick J. Christmas II, J.D.,
Chief Legal Officer -
Patrick J. Christmas II,
Chief Legal Officer -
Dr. Stephen Pakola,
Chief Medical Officer -
Luke Beshar,
Independent Director -
David Stump,
Independent Director -
Daniel Abdun-Nabi,
Independent Director -
A. N. Karabelas,
Lead Independent Director -
Daniel Tasse,
Independent Director -
Alexandra Glucksmann,
Independent Director -
Allan Fox,
Chairman of the Board -
Dr. Laura A. Coruzzi J.D., Ph.D.,
Sr. VP of Intellectual Property -
Ram Palanki,
Sr. VP of Commercial Strategy & Operations -
Dr. Laura A. Coruzzi,
Sr. VP of Intellectual Property -
Shiva G. Fritsch,
Chief People Officer -
Andrew Yost,
VP of Corp. Devel. -
Tricia Truehart,
VP of Investor Relations & Corp. Communications -
Stephen Yoo,
Chief Medical Officer -
Llc Fmr,
10% owner -
Camille D Samuels,
Director -
Faraz Ali,
Chief Business Officer -
Edgar Engleman,
Director -
James E Deerfield Mgmt L.P....,
-
Donald J Jr Hayden,
-
Patrick J. Christmas,
Chief Legal Officer -
Jean Bennett,
-
George V Migausky,
-
Jennifer Zachary,